Gilead Reveals Leadership Transition As Milligan Takes CEO Role
This article was originally published in Scrip
Executive Summary
Gilead Sciences Inc. faced a lot of bad news related to its hepatitis C drugs during the last week of January, so there might have been a better time to announce a changing of the guard in the company's C-suite, no matter how much shareholders anticipated the succession plan.